

## Treatment of Invasive Fungal Infections: Stability of Voriconazole Infusion Solutions in PVC Bags

Andréa I.H. Adams, Lucia N. Morimoto, Leonardo Z. Meneghini and Ana M. Bergold  
Pharmacy School of Federal University of Rio Grande do Sul (UFRGS); Porto Alegre, RS, Brazil

Voriconazole is a novel broad-spectrum antifungal drug, employed in the treatment of invasive fungal infections, and represents an alternative to amphotericin B treatment. The manufacturer recommends that any unused reconstituted product should be stored at 2°C to 8°C, for no more than 24 h, but no recommendations about i.v. infusion solutions are given. Previous works have reported on the stability of voriconazole in polyolefin bags and just one in 5% dextrose polyvinyl chloride (PVC) bags, at a 4 mg.mL<sup>-1</sup> concentration. In this work, the stability of voriconazole as an i.v. infusion solution in 0.9% sodium chloride and in 5% dextrose, in PVC bags, at 0.5 mg.mL<sup>-1</sup>, stored at 4 °C and at room temperature, protected from light, was evaluated. These infusion solutions were analyzed for a 21-day period. Chemical stability was evaluated by HPLC assay. Visual inspection was performed and pH of the solutions was measured. No color change or precipitation in the solutions was observed. The drug content remained above 90% for 11 days in 0.9% sodium chloride and for 9 days in 5% dextrose solutions. The i.v. infusion solutions stored at room temperature were not stable. At room temperature, the voriconazole content dropped down to 88.3 and 86.6%, in 0.9% sodium chloride or 5% dextrose solutions, respectively, two days after admixture. Assays performed at the end of the study suggest the sorption of voriconazole by the PVC bags. The results of this study allow cost-effective batch production in the hospital pharmacy.

**Key-Words:** Antifungal drugs, voriconazole, voriconazole stability, voriconazole infusion solutions, PVC bags.


The past two decades have witnessed an increase in the incidence of nosocomial fungal infections. Fungal sepsis has increased by more than 200% in this period [1] and represents a major problem, given the relatively poor response rates, especially for aspergillosis, and the high cost of the therapies [2]. The increase in the incidence of fungal infections may be attributed primarily to increased numbers of critically ill and immunocompromised patients, including those with AIDS, cancer patients undergoing chemotherapy, and organ transplant recipients taking immunosuppressive drugs. Other possible reasons for the increased incidence of fungal infections include the growing number of patients undergoing invasive medical procedures, receiving broad-spectrum antibiotics or long-term corticosteroid therapy and receiving parenteral nutrition or hemodialysis [3].

*Candida* is responsible for ca. 80% of nosocomial fungal infections, with *Candida albicans* being the predominant *Candida* pathogen [4]. *Aspergillus* spp. are less common, causing ca. 4% to 5% of nosocomial fungal infections [3]. These pathogens are related to an extremely high mortality rate: around 40% to 60% for *Candida* [5] and 85% for *Aspergillus* [3], even with aggressive antifungal therapy. Although *Candida* and *Aspergillus* species still represent the vast majority of fungal isolates encountered in human pathology, a number of new species – both yeasts and filamentous fungi – are increasingly recognized as opportunistic pathogens [6,7].

The number of available antifungal agents suitable for treating systemic fungal infections is limited. Until recently, the arsenal that was available consisted mainly of the polyene antibiotic amphotericin B, some azole derivatives, the allylamines-thiocarbamates and 5-flucytosine. In the past decade, however, new compounds were licensed, including azole compounds and the candins [7]. Voriconazole (Figure 1) is an azole compound, structurally related to fluconazole, where one of the triazole moieties was replaced by a fluoropyrimidine group and an alpha methyl group was introduced. These modifications resulted in an enhanced spectrum of antifungal activity and in increased *in vitro* potency [8].

Amphotericin B deoxycholate and voriconazole are the only two antifungal medications currently approved as primary therapy for invasive aspergillosis infection in the U.S.. Second line treatments include lipid-based formulations of amphotericin, itraconazole and caspofungin [9,10].

**Figure 1.** Chemical structure of voriconazole.



Received on 10 April 2008; revised 18 September 2008.

Address for correspondence: Dr. Ana M. Bergold. Faculdade de Farmácia - Universidade Federal do Rio Grande do Sul. Av. Ipiranga, 2752. CEP 90610-000. Porto Alegre, RS/Brasil. ana.bergold@ufrgs.br.

The Brazilian Journal of Infectious Diseases 2008;12(5):400-404.  
© 2008 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved.

Voriconazole was authorized for use by the FDA in the U.S. and by ANVISA in Brazil in 2002, for the treatment of invasive fungal infections [6]. It is especially recommended for the treatment of invasive aspergillosis and of infections caused by *Scedosporium*, *Fusarium* spp and resistant *Candida* species [11].

Voriconazole is available as an injection, tablets and oral suspension. The i.v. product is supplied in a single-use vial containing 200 mg of voriconazole and 3,200 mg of sulfobutyl ether beta-cyclodextrin sodium, which makes the drug soluble and allows its parenteral administration. The powder must be reconstituted with sterile water for injection and this solution must be diluted to a final concentration of 0.5 to 5 mg/mL with suitable diluents, such as 0.9% sodium chloride or 5% dextrose [12].

The manufacturer recommends that any unused reconstituted solution should be discarded after 24 h, since it has been demonstrated to be stable for this period, stored at 2 to 8 °C. There are no recommendations about the stability of the infusion solutions or about their compatibility with different polymers of infusion bags [12]. In relation to the stability of infusion solutions, it was reported that 2 mg.mL<sup>-1</sup> voriconazole in 0.9% sodium chloride infusion bags is stable at 2-8 °C for 32 days; the same shelf life was verified for the reconstituted product [13]. It was also reported that 2 mg.mL<sup>-1</sup> voriconazole, protected from light, was stable for eight days when stored at 4 or 25 °C diluted in 0.9% sodium chloride solution, and for six days at 4 °C and four days at 25 °C in 5% dextrose solution [14]. In both studies, voriconazole was stored in multilayer polyolefin bags. The stability of voriconazole was studied in PVC bags, at 4 mg.mL<sup>-1</sup> in 5% dextrose, stored at 4 °C. Under these conditions, voriconazole solutions are stable for 15 days [15].

The role voriconazole plays in the treatment of fungal infections, the high cost of the therapy, and the dose adjustments which produce residual product justify more studies on its stability. The aim of this work was to study the stability of voriconazole as i.v. infusion solutions in PVC bags, in a diluent other than dextrose, since for some patients this diluent is not recommended. The chemical stability of voriconazole was determined as infusion solutions in 0.9% sodium chloride and 5% dextrose, stored in PVC bags over 21 days, maintained at 4-7 and 19-24 °C, at 0.5 mg.mL<sup>-1</sup>. This concentration represents the lowest concentration recommended for an i.v. infusion solution.

## Material and Methods

### Reagents and Drugs

Vials of lyophilized voriconazole powder (Vfend® 200 mg, Pfizer, lot 5163904) were reconstituted with 19 mL of sterile water for injection to yield 20 mL of 10 mg.mL<sup>-1</sup> solution. PVC bags containing 0.9% sodium chloride injection (50 mL, Halex Istar, lot IB 607/05) and 5% dextrose injection (100 mL, Halex Istar, lot IB 631/03) were used. Voriconazole standard, with an assigned purity of 99.75% was provided by Gencor Pacific

Limited, Hong Kong. For high-performance liquid chromatography assay, methanol (HPLC grade, Merck, Germany), triethylamine and orthophosphoric acid reagent grade (Merck, Germany), and distilled water purified by a MilliQ Plus water system (Millipore, USA) were used.

### Chromatographic Apparatus and Conditions

A Shimadzu HPLC system (Kyoto, Japan) provided with a LC-10AD<sub>VP</sub> pump, a Rheodyne® manual injector (model 7725i), a SPD-M10A<sub>VP</sub> diode array detector, DGU-14A degas and an SCL-10A<sub>VP</sub> controller with CLASS-VP software was employed. The chromatographic analyses were performed on a Merck LiChrospher® 100 RP-8 (125 x 4.6 mm I.D., 5 mm particle size) column. The mobile phase was composed of methanol/0.6% triethylamine, pH 6.0 (50:50 v/v), at a flow rate of 1 mL.min<sup>-1</sup>, and the injection volume was 20 µL. UV detection was performed at 255 nm and the identity of peaks was determined by comparing the elution times and ultraviolet spectra of samples and standard solution, supplied by the PDA detector.

### HPLC Analysis

Voriconazole concentrations were determined by a stability-indicating HPLC method previously described in the literature [16], employing exactly the same conditions that are described in the *Chromatographic apparatus and conditions* section. Chromatographic parameters which allow the adjustment of system performance, were monitored.

The applied method was linear in the range of 0.02 to 0.1 mg.mL<sup>-1</sup>, with a coefficient of correlation of 0.9999 and a linear regression equation of  $y = -923.76 + 27569.82x$ . The method was examined for specificity by carrying out forced degradation studies which demonstrated that voriconazole is sensitive to alkali, acid and oxidizing media, where degradation in alkaline conditions is faster and more intense. In all the conditions employed, peaks of degradation products, when observed (retention times: 2.6 to 7.7 min) were resolved from the voriconazole peak (retention time: 8.4 min) [16].

In this study, specificity and precision of the assay were evaluated again. The specificity was assessed by the peak purity of all voriconazole peaks, given by the PDA detector. To be considered pure, the peak purity index should be higher than 0.99 [17]. The precision of the method was evaluated by the intra-day relative standard deviation values (RSD) between all the duplicate samples assayed, where RSD values ≤ 2.0% were considered acceptable.

### Stability Study

For the preparation of the i.v. infusion solutions, 2.5 mL of freshly prepared reconstituted product were introduced into 50 mL of 0.9% sodium chloride or 100 mL of 5% dextrose PVC bags, from which 2.5 mL and 52.5 mL were previously withdrawn, respectively, to obtain a voriconazole concentration of 0.5 mg.mL<sup>-1</sup>. The bags were then shaken to ensure thorough mixing. Three bags of voriconazole were prepared for each of the infusion solutions and temperatures assayed.

The i.v. infusion solutions were stored under refrigeration (4-7 °C) or at room temperature (19-24 °C), in the dark. They were analyzed at 0, 2, 4, 7, 9, 11, 14 and 21 days. Before the analysis was conducted, the bags were allowed to reach room temperature and mixed well before sample collection. One milliliter was taken from each of the three bags and diluted with water to 0.05 mg.mL<sup>-1</sup>, and each bag was assayed in duplicate. Since the method was linear in the range of 0.02 to 0.1 mg.mL<sup>-1</sup> [16], even if degradation occurred, the solution concentrations remained in the linear range of the analytical method. The voriconazole reconstitution, the preparation of the i.v. infusion solutions and the sampling at each time were performed using aseptic technique.

The quantification was performed comparing the mean areas of the standard solutions at a concentration of 0.05 mg.mL<sup>-1</sup> with the sample solutions. The initial concentrations (day 0) were defined as 100% and subsequent concentrations were expressed as percentages of the initial concentration. The results were reported as means ± S.D. of the percentages of the initial concentration. The drug solutions were defined as stable if more than 90% of the initial concentration was maintained. The pH was measured with a pH meter at the beginning and at the end of the study (DM 20-Digimed). The appearance and color were accessed by observing samples against black and white backgrounds.

At the end of the study, the bags were totally emptied and washed several times with water, where the last portion of the washing solutions was saved. A-20 mL volume of methanol was added to the bags, which were maintained in a horizontal position and allowed to be in contact with the solvent for 5 days. After this period, an aliquot of the methanol solution and the final washing solution were analyzed by HPLC assay.

## Results and Discussion

Considering the clinical relevance of voriconazole in the treatment of invasive fungal infections, the high cost of this therapy and the lack of studies about its stability, this study was carried out to determine drug stability in the diluents and storage conditions usually employed in Brazilian hospitals. Voriconazole powder for i.v. infusion solutions must be first

reconstituted with sterile water for injection and then diluted with appropriate diluents. There are no recommendations with regard to the stability of the infusion solution or about its compatibility with different polymers of infusion bags in the package insert [12]. Two studies reported in the literature employed polyolefin bags (PVC-free) [13,14] and another one used PVC bags [15]. The latter reported voriconazole stability in 5% dextrose solution, a diluent not recommended for some patients. In the present study, drug stability in PVC bags containing 0.9% sodium chloride injection was also studied. The cost of polyolefin bags is twice that of PVC bags. In Europe, around 60% of the bags used are made of PVC, and in the U.S., around 80%. In Brazil, closed system PVC bags are being introduced, which will reduce the most important problem related to the open system bags currently used: the risk of contamination.

The degradation of voriconazole was determined by a stability indicating method, previously validated [16]. Moreover, chromatographic parameters and specificity of the assay were monitored. The chromatographic parameters determined indicate that the conditions tested provided a well-behaved chromatographic system, essential for accurate and precise results. The following values were obtained: theoretical plates ≥ 2,500, tailing factor ≤ 1.6 and capacity factor ≤ 7.6, all of which are in accordance with established values [18]. The specificity of the assay was evaluated again in this experiment, employing a PDA detector. To be considered specific, which is an essential characteristic for stability studies, an assay method should demonstrate that it is able to separate and quantify the drug from a physical mixture of the drug, degradation products and excipients. As mentioned in the *HPLC analysis section*, the voriconazole peak was resolved from the peaks of the degradation products, obtained in the forced degradation studies [16]. Besides, the peak purity index was determined by the PDA detector, the most popular technique used to assay it. The purity of the peak attributed to voriconazole was higher than 0.9999 in all assays, showing that no impurities or degradation products or excipients coeluted with the parent drug, indicating the specificity of the analytical method [17]. The precision of the assay was

**Table 1.** Stability of 0.5 mg/mL voriconazole in 0.9% sodium chloride and 5% dextrose at 4-7 and 19-24 °C.

Diluent and storage temperature	Initial concentration (mg/mL)	% initial drug concentration remaining ± SD <sup>a</sup>						
		Day 2	Day 4	Day 7	Day 9	Day 11	Day 14	Day 21
0.9% sodium chloride								
4-7 °C	0.52 ± 0.03	92.3 ± 1.2	91.7 ± 1.2	91.7 ± 0.6	91.2 ± 1.9	91.5 ± 1.2	89.1 ± 1.0	87.3 ± 0.6
19-24 °C	0.47 ± 0.02	88.3 ± 1.3	83.2 ± 1.1	76.4 ± 0.7	75.2 ± 1.3	76.0 ± 1.3	71.6 ± 0.8	63.6 ± 2.4
5% dextrose								
4-7 °C	0.50 ± 0.01	92.4 ± 0.9	93.6 ± 1.0	92.2 ± 0.7	92.9 ± 1.2	87.7 ± 1.9	89.2 ± 2.5	88.0 ± 0.4
19-24 °C	0.51 ± 0.01	86.6 ± 0.7	87.9 ± 2.1	82.4 ± 0.9	80.9 ± 3.1	75.9 ± 1.3	75.5 ± 0.5	69.7 ± 2.3

<sup>a</sup> Standard deviation.

confirmed by intra-day relative standard deviation (RSD) values less than 2.0%.


No color changes, haziness or precipitation were observed in the infusion solutions until the end of the study. The pH values decreased slightly during the period of analysis: from  $5.93 \pm 0.09$  to  $5.80 \pm 0.10$  and from  $5.90 \pm 0.12$  to  $5.60 \pm 0.08$ , for 0.9% sodium chloride solutions, maintained at 4°C or at room temperature, respectively. Similar results were observed for the dextrose solutions, which showed a decrease from  $4.42 \pm 0.10$  to  $4.30 \pm 0.13$  and from  $4.29 \pm 0.09$  to  $4.15 \pm 0.06$ , stored at 4°C or at room temperature, respectively.

Table 1 presents the results obtained in the stability test. The percentages of the initial concentration indicate that the compound was stable in 0.9% sodium chloride for 11 days and for 9 days in 5% dextrose solutions, stored at 4°C in PVC bags, protected from light. The infusion solutions maintained under refrigeration were more stable than those maintained at


room temperature, an effect observed in both diluents. At room temperature, the drug content percentages dropped to 88.3 and 86.6, in 0.9% sodium chloride and 5% dextrose solutions, respectively, only two days after preparation. The faster decrease of drug content in the bags stored at room temperature was also observed by Sahraoui et al. (2006) who studied the stability of voriconazole in polyolefin bags [14].

No degradation products were formed in the samples stored at 4°C or room temperature, which can be observed in chromatograms obtained at day 21 (Figure 2). This result suggests that the degradation products do not have a chromophore group, that voriconazole was decomposed to low molecular weight fractions or that sorption of voriconazole by the PVC bags occurred. In order to confirm the latter possibility, the PVC bags were totally emptied, washed with water, where the last portion of washing solution was saved. Methanol was introduced and kept inside the bags for 5 days,


**Figure 2.** Chromatograms of voriconazole infusion solution in 0.9% sodium chloride (A) and in 5% dextrose (B) at zero time and day 21 after admixture, maintained at 4-7°C.



**Figure 3.** Chromatograms of voriconazole, extracted with methanol from PVC bags that previously contained voriconazole in 0.9% sodium chloride, after 5-day period of contact (A); last washing aqueous solutions (B).



**Figure 4.** Chromatograms of voriconazole, extracted with methanol from PVC bags that previously contained voriconazole in 5% dextrose, after 5-day period of contact (A); last washing aqueous solutions (B).



in order to extract any bound drug from the bags. Voriconazole was detected in the methanol solutions (Figures 3A and 4A), but not in the washing solutions (Figures 3B and 4B). This fact suggests that the amount in the methanol solutions came exclusively from adsorbed and/or absorbed drug. As noted in previous works, the pH of the solution is an essential factor that influences the sorption of drugs by PVC bags. The non-ionized drug species are more lipophilic and thus, more favorably absorbed by the plastic [19-22]. The relative amount of non-ionized form depends on the solution pH and on the drug pKa. Voriconazole is a weak base (pKa 1.76) [23] and in the range of pH values obtained at the end of the study (5.93 to 4.15), the percentage of non-ionized drug form is higher than 99.5%. A faster decrease in pH was observed in infusion solutions stored at room temperature. As previously reported [21], higher temperatures can increase the solute diffusion rate through the plastic matrix, increasing drug binding.

Analysis made by PDA detector at day 21 showed no other peaks in the visible and UV range and the purity of voriconazole peak, which reinforces the notion of drug sorption by the bags.

The result obtained here differs, in part, from that obtained by Cadrobbi et al. [16]. They found that voriconazole in 5% dextrose solution, stored at 4°C, at a concentration of 4 mg.mL<sup>-1</sup>, was stable for a 15-day period, while we found a 9-day stability period. This difference can be an effect of the voriconazole concentration, since we used the lowest concentration recommended by the manufacturer, 0.5 mg.mL<sup>-1</sup>. Moorhatch and Chiou [19] reported different sorption effects with PVC bags depending on drug concentration. For vitamin A and methohexital, the bound percentage is not influenced by concentration. On the other hand, an increase in warfarin concentration results in a decrease in the bound percentage. Thus, in the last case, more dilute solutions lost a higher percent of total drug to the plastic, as observed in the present study. However, other studies showed no correlation between drug sorption and concentration [20,21]. Therefore, the question about concentration effect posed here should be examined by additional studies, employing other voriconazole concentrations.

## Conclusion

The present study shows that voriconazole as an infusion solution in PVC bags, at 0.5 mg.mL<sup>-1</sup>, stored at 4-7°C and protected from light, is stable for 11 days in 0.9% sodium chloride and for 9 days in 5% dextrose solutions. At room temperature, stored in PVC bags and protected from light, i.v. solutions are stable for less than 2 days, suggesting that they should be administered immediately after their preparation. These results allow a reduction of costs by batch production at the hospital pharmacy. Considering that there is no preservative in voriconazole injection, the reconstitution and i.v. admixtures should be carried out in aseptic areas, in order to avoid microbial contamination and to allow its use for the suggested periods, for which its chemical stability was determined.

## Acknowledgements

The authors wish to thank CNPq for the research grants, Cristalia Laboratories for the supply of voriconazole reference substance, Farmoterápica for the donation of PVC bags and São Vicente de Paulo Hospital for the supply of voriconazole injection.

## References

- Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* **2003**;348:1546-54.
- Klastersky J. Empirical antifungal therapy. *Int J Antimicrob Agents* **2004**;23:105-12.
- Stone E.A., Fung H.B., Kirschenbaum H.L. Caspofungin: an echinocandin antifungal agent. *Clin Ther* **2002**;24:351-77.
- Wilson L., Reyes C.M., Stolpmann M., et al. The direct cost and incidence of systemic fungal infections. *Value Health* **2002**;5:26-34.
- Colombo A.L., Guimarães T. Epidemiologia das infecções hematogênicas por *Candida* spp. *Rev Soc Bras Med Trop* **2003**;36:599-607.
- Moretti M.L. A importância crescente das infecções fúngicas. *Rev Panam Infect* **2007**;9.
- Maertens, J.A. History of the development of azole derivatives. *Clin Microbiol Infect* **2004**;10:1-10.
- Fromtling R.A., Castañer J. Voriconazole. *Drugs Fut* **1996**;21:266-71.
- Lewis J.S., Boucher H.W., Lubowski T.J., et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. *Pharmacotherapy* **2005**;25:839-46.
- Wenzel R., Del Favero A., Kibbler C., et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. *J Antimicrob Chemother* **2005**;55:352-61.
- Donnelly J.P., De Pauw B.E. Voriconazole – a new therapeutic agent with an extended spectrum of antifungal activity. *Clin Microbiol Infect* **2004**;10:107-17.
- Package insert. Vfend® (voriconazole). Pfizer Laboratories.
- Hoppe-Tichy T., Wenzel S., Gehrig A.K., Nguyen H. Stability of voriconazole in infusion bags. *Pharmazie* **2005**;60:77-8.
- Sahraoui L., Chiadmi F., Schlatter J., et al. Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections. *Am J Health-Syst Pharm* **2006**;63:1423-26.
- Cadrobbi J., Hecq J.P., Lebrun C., et al. Long-term stability of voriconazole 4 mg/mL in 5% dextrose polyvinyl chloride bags at 4 °C. *EJHP Science* **2006**;12:57-9.
- Adams A.I.H., Bergold A.M. Development and validation of a high performance liquid chromatographic method for the determination of voriconazole content in tablets. *Chromatographia* **2005**;62:429-34.
- Watson D.G. *Pharmaceutical Analysis. A Textbook for pharmacy students and pharmaceutical chemists.* Edinburgh: Elsevier Churchill Livingstone, **2005**.
- CDER. Center for Drug Evaluation and Research – FDA. Reviewer guidance for validation of chromatographic methods **1994**.
- Moorhatch P., Chiou W.L. Interactions between drugs and plastic intravenous fluids bags. Part I: sorption studies on 17 drugs. *Am J Hosp Pharm* **1974**;31:72-8.
- Kowaluk E.A., Roberts M.S., Balckburn H.D., Polack A.E. Interactions between drugs and polyvinyl chloride infusion bags. *Am J Hosp Pharm* **1981**;38:1308-14.
- Illum L., Bundgaard H. Sorption of drugs by plastic infusion bags. *Int J Pharm* **1982**;10:339-51.
- Lackner T.E., Baldus D., Butler C.D., et al. Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. *Am J Hosp Pharm* **1983**;40:97-101.
- Captisol®. [www.captisol.com/Captisol/ProductApprovals.pdf](http://www.captisol.com/Captisol/ProductApprovals.pdf). (accessed on **04/20/05**).